CN101679265B - 异磷酰胺芥及其类似物的盐 - Google Patents

异磷酰胺芥及其类似物的盐 Download PDF

Info

Publication number
CN101679265B
CN101679265B CN200880018371.5A CN200880018371A CN101679265B CN 101679265 B CN101679265 B CN 101679265B CN 200880018371 A CN200880018371 A CN 200880018371A CN 101679265 B CN101679265 B CN 101679265B
Authority
CN
China
Prior art keywords
dosage
ipm
ipmtris
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880018371.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679265A (zh
Inventor
J·C·阿梅迪奥
B·P·沃尔纳
P·B·科马尼特斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ziopharm Oncology Inc
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101679265(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Priority to CN201210399034.3A priority Critical patent/CN102942589B/zh
Publication of CN101679265A publication Critical patent/CN101679265A/zh
Application granted granted Critical
Publication of CN101679265B publication Critical patent/CN101679265B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CN200880018371.5A 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐 Expired - Fee Related CN101679265B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210399034.3A CN102942589B (zh) 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US92214807P 2007-04-06 2007-04-06
US60/922,148 2007-04-06
US92736307P 2007-05-02 2007-05-02
US60/927,363 2007-05-02
US93491407P 2007-06-15 2007-06-15
US60/934,914 2007-06-15
US123707P 2007-10-30 2007-10-30
US61/001,237 2007-10-30
PCT/US2008/004449 WO2008124097A2 (en) 2007-04-06 2008-04-04 Salts of isophosphoramide mustard and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210399034.3A Division CN102942589B (zh) 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐

Publications (2)

Publication Number Publication Date
CN101679265A CN101679265A (zh) 2010-03-24
CN101679265B true CN101679265B (zh) 2014-10-29

Family

ID=39387443

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880018371.5A Expired - Fee Related CN101679265B (zh) 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐
CN201210399034.3A Expired - Fee Related CN102942589B (zh) 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210399034.3A Expired - Fee Related CN102942589B (zh) 2007-04-06 2008-04-04 异磷酰胺芥及其类似物的盐

Country Status (22)

Country Link
US (2) US8604007B2 (https=)
EP (2) EP2581367B1 (https=)
JP (1) JP5659010B2 (https=)
KR (3) KR101505415B1 (https=)
CN (2) CN101679265B (https=)
AU (1) AU2008236684B2 (https=)
BR (1) BRPI0809999A2 (https=)
CA (1) CA2684747A1 (https=)
CY (1) CY1116596T1 (https=)
DK (2) DK2155682T3 (https=)
ES (1) ES2547302T3 (https=)
HU (1) HUE025949T2 (https=)
IL (2) IL201424A (https=)
MX (1) MX2009010820A (https=)
NZ (1) NZ580341A (https=)
PL (1) PL2155682T3 (https=)
PT (2) PT2581367E (https=)
RU (1) RU2527531C2 (https=)
SI (1) SI2155682T1 (https=)
TW (2) TWI490226B (https=)
WO (1) WO2008124097A2 (https=)
ZA (1) ZA200907722B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336140B1 (en) * 2004-10-25 2016-01-27 Dekk-Tec, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7964583B2 (en) * 2006-02-17 2011-06-21 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
MX2009010820A (es) 2007-04-06 2010-03-18 Ziopharm Oncology Inc Sales de mostaza isofosforamida y analogos de la misma.
NZ601139A (en) * 2008-07-31 2014-02-28 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
AU2010218109B2 (en) * 2009-02-24 2015-04-09 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
US20130196000A1 (en) * 2012-01-31 2013-08-01 Ziopharm Oncology, Inc. Combination therapy including isophosphoramide mustard, analogs, or salts thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047575A2 (en) * 2004-10-25 2006-05-04 Dekk-Tec Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU427945A1 (ru) 1972-07-24 1974-05-15 Институт элементоорганических соединений СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ
JPS5159886A (https=) 1974-11-20 1976-05-25 Shionogi Seiyaku Kk
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
US5468499A (en) * 1993-11-15 1995-11-21 Ohio State University Liposomes containing the salt of phosphoramide mustard and related compounds
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
DE60007120T2 (de) 1999-05-24 2004-09-16 Southern Research Institute, Birmingham Isophosphoramide-senfgasanalogen und deren verwendung
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
GB2378948B (en) 2000-04-13 2004-11-10 Hsc Res Dev Lp Novel compounds for modulating cell proliferation
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
MX2009010820A (es) 2007-04-06 2010-03-18 Ziopharm Oncology Inc Sales de mostaza isofosforamida y analogos de la misma.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047575A2 (en) * 2004-10-25 2006-05-04 Dekk-Tec Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide;N. Germann S. et al.;《Cancer Chemother Pharmacol》;20040914;第55卷;143-151 *

Also Published As

Publication number Publication date
MX2009010820A (es) 2010-03-18
CN102942589B (zh) 2016-04-20
ZA200907722B (en) 2010-11-24
TWI490226B (zh) 2015-07-01
KR20090130098A (ko) 2009-12-17
EP2155682A2 (en) 2010-02-24
PT2581367E (pt) 2016-03-28
NZ580341A (en) 2012-06-29
JP5659010B2 (ja) 2015-01-28
CA2684747A1 (en) 2008-10-16
IL201424A0 (en) 2010-05-31
CY1116596T1 (el) 2017-03-15
JP2010523571A (ja) 2010-07-15
SI2155682T1 (sl) 2015-11-30
KR20130041391A (ko) 2013-04-24
AU2008236684A1 (en) 2008-10-16
KR101505415B1 (ko) 2015-03-25
AU2008236684B2 (en) 2013-04-18
IL223353A (en) 2016-02-29
US9340563B2 (en) 2016-05-17
EP2581367A2 (en) 2013-04-17
TW201406772A (zh) 2014-02-16
US8604007B2 (en) 2013-12-10
BRPI0809999A2 (pt) 2014-10-14
DK2581367T3 (en) 2016-03-14
KR101604244B1 (ko) 2016-03-17
PL2155682T3 (pl) 2015-12-31
CN102942589A (zh) 2013-02-27
TW200906842A (en) 2009-02-16
US20140194377A1 (en) 2014-07-10
CN101679265A (zh) 2010-03-24
EP2581367B1 (en) 2015-12-30
US20080255056A1 (en) 2008-10-16
DK2155682T3 (en) 2015-09-21
EP2581367A3 (en) 2013-07-03
IL201424A (en) 2016-02-29
WO2008124097A3 (en) 2008-12-24
PT2155682E (pt) 2015-10-15
HUE025949T2 (en) 2016-05-30
RU2527531C2 (ru) 2014-09-10
IL223353A0 (en) 2013-02-03
ES2547302T3 (es) 2015-10-05
RU2009140904A (ru) 2011-05-20
EP2155682B1 (en) 2015-06-24
KR20150139620A (ko) 2015-12-11
TWI501972B (zh) 2015-10-01
WO2008124097A2 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
ES2719052T3 (es) Terapia de combinación con un antibiótico antitumoral
CN101679265B (zh) 异磷酰胺芥及其类似物的盐
ES2970251T3 (es) Profármacos antivirales y nanoformulaciones de los mismos
CN104558023A (zh) 作为抗肿瘤剂的异磷酰胺氮芥及其类似物的盐
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
CN109223791A (zh) 脑癌的治疗
CA3126348A1 (en) Antiviral prodrugs and formulations thereof
CN112370456A (zh) 新配方
KR20120008069A (ko) 카바지탁셀 및 카페시타빈을 포함하는 항종양 조합물
US10004694B2 (en) Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same
CN107613984A (zh) 药物组合物及其用途
AU2009276512B2 (en) Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
JP3219402B2 (ja) 多発性骨髄腫の骨病変治療用医薬組成物
EP3570860B1 (en) Anticancer heterobasidion annosum extract, compositions and uses thereof
US20250367301A1 (en) Pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising oligonucleotide as active ingredient
Khan Business and Market of Material Products for Medical Applications—Material-Based Products, Business and Profits of Products, Major Market Players, Global Trends, Investments, and Future Opportunities
Repp Oligo (lactic Acid) 8-docetaxel Prodrug Loaded and Oligo (lactic Acid) 8-paclitaxel and Oligo (lactic Acid) 8-rapamycin Prodrug Co-loaded PEG-b-pla Micelles for Injection
Shakil Implantable polymeric prodrug candidates for sustained release antiretroviral therapy
HK1185884A (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20170404